

30 JUNE 2023 TRISTEL PLC PRELIMINARY RESULTS INVESTOR PRESENTATION

> Paul Swinney, CEO Liz Dixon, CFO Heidi Allard, CFC


16-19 October 2023

Our Company

Global infection prevention

• Focus on healthcare

• Unique proposition: chlorine dioxide




Simple, focussed, global opportunity



Multiple Applications


Tristel

Department	Medical Device	Revenue
Obs & gynae	Trans-vaginal u/sound probes	
Radiology	Trans-rectal u/sound probes	£11.7m
Hospital wide	Skin-surface u/sound probes	
Cardiology	Echo cardio probes	£7.4m
ENT	Nasendoscopes	£6.8m
A&E & theatres	Intubation laryngoscopes	£1.5m
Ophthalmology	Tonometers	£1.2m
Urology	Cystoscopes	£0.6m
Other	Various	£1.6m



5

Ambition: "Global market leader in emerging niche - sporicidal surface disinfectants"



Financial Highlights

- 16% growth in turnover to £36.0m (2022: £31.1m)
- 22% growth from continuing products to £36m (2022: £29.6m)
- Overseas sales up 17% to £23.5m (2022: £20.1m) = 65% of total sales (2022: 65%)
- Gross margin 81% (2022: 80%)
- Adjusted EBITDA* margin of 25% (2022: 24%)
- Adjusted pre-tax profit* of £6.2m (2022: £4.5m) slightly above consensus forecasts
- Reported pre-tax profit of £5.1m (2022: £1.6m)
- Adjusted EPS* of 10.67p up 39% (2022: 7.68p). Reported EPS of 9.44p (2022: 2.09p)
- Dividend per share for the full year up 10% to 10.50p (2022: 9.55p)
- Net cash & deposits of £9.5m (2022: £8.9m) strong operating cashflow of £8.5m (2022: £5.6m)

* before share-based payments and 2022 impairment of intangibles



Operational Highlights

- US FDA Class II device approval for Tristel ULT as a high-level disinfectant for ultrasound probes, with nationwide launch underway
- Regulatory approval in Canada for Tristel OPH as a high-level disinfectant for ophthalmic devices with first sales recorded in Q1 FY 2024
- Majority of UK and European regulatory approvals for Cache product range expected to be secured in FY 2024
- Continued investment in exciting pipeline of new product innovations
- Global headcount 224 (2022: 204)

Post-period end: US manufacturing has commenced and first products shipped



10 Year Growth - CAGR 13%





Sales Growth by Geography

£m	2021-22	2022-23	Year on year change	% change
Australasia	4.0	4.6	0.6	15%
China & Hong Kong	1.7	2.0	0.3	18%
Malaysia & Singapore	0.6	0.8	0.2	33%
Western Europe	4.8	5.8	1.0	21%
Central Europe	5.4	6.1	0.7	13%
Southern Europe	1.0	1.4	0.4	40%
Overseas distributors	2.6	2.8	0.2	8%
Total overseas sales	20.1	23.5	3.4	17%
Total UK sales	11.0	12.5	1.5	14%
Global sales	31.1	36.0	4.9	16%
- Wholly owned sub	sidiary selling directly to h	ospital markat	Thir rty distributor	

= Wholly owned subsidiary, selling directly to hospital market

= Thir rty distributor



Sales Growth by Portfolio and Channel

£m		2021-22	2022-23	Y-O-Y change	% change
	UK direct	7.6	9.5	1.9	25%
Tristel Hospital Medical Device	EMEA direct	10.5	12.5	2.0	19%
Decontamination	APAC direct	5.3	6.4	1.1	21%
Decontainnation	Worldwide distributors	2.0	2.4	0.4	20%
		25.4	30.8	5.4	21%
Casha	UK direct	2.1	2.2	0.1	5%
Cache Hospital Surface Disinfection	EMEA direct	0.4	0.4	-	-
nospital surface disinfection	APAC direct	0.5	0.5	-	-
	Worldwide distributors	0.2	0.2	-	-
		3.2	3.3	0.1	3%
Other	All geographies and channels	1.0	1.9	0.9	90%
Continuing products		29.6	36.0	6.4	22%
Discontinuations		1.5	0	(1.5)	-
Total		31.1	36.0	4.9	16%



FY24 Tailwinds & Headwinds

Positive:

- Diagnostic procedures are increasing organically in all countries
- Hospital selection of appropriate surface disinfectants is better informed
- Unprecedented concern around single-use pre-wetted wipes
- Some insulation from inflation and energy cost pressures
- Pricing power aligned to global inflation rate

Negative:

- Under-resourced regulators
- Hospital staff shortages / further COVID waves / UK industrial action





Product Development







3T platform: App-based Train, Trace and Test tool to record all steps of the decontamination process.

AI:

Capabilities incorporated into the app for objective verification that the key steps are performed correctly.

Colour change technology: Visual indicators to ensure key steps in the decontamination process are performed correctly.

62 patent applications, 6 applications went to grant. £0.9m invested in product development and £0.3m in securing and maintaining intellectual property protection.



North America - Product Strategy

USA

Tristel ULT

- High level disinfectant
- Ultrasound probes
- FDA De Novo
- On sale



Canada

Duo OPH

- High level disinfectant
- Ophthalmic devices
- Health Canada
- On sale

Duo ULT

Tristel DUO

EPA

On sale

Low/mid level disinfectant

Ultrasound equipment

- High level disinfectant
- Ultrasound probes
- Health Canada
- Dossier submitted



Next: USA: Tristel OPH

- High level disinfection
- Ophthalmic devices
- FDA 510k
- Testing started

USA: Tristel ORL

- High level disinfection
- Ear, Nose & Throat devices
- FDA 510k
- Testing stage

Canada: Duo ORL

- High level disinfection
- Ear, Nose & Throat devices
- Health Canada
- Testing stage



North America - Operational Update

Manufacturing:

- Process validation complete
- Production underway & inventory available

Sales and marketing:

- First orders shipped & invoiced
- Parker distributors include: Medline Industries / Henry Schein / Owens & Minor / McKesson Corp
- Listing in hospital and distributor procurement systems underway
- FY24 Parker exhibiting at 7 major USA conferences and Innova at 2 major Canadian conferences, supported by Tristel team



FY23 - FY25 Financial Targets

Returning to growth


- Sales growth in the range of 10% to 15% per annum as an annual average over the three years (Over 14 year period to FY19 CAGR was 17%)
- EBITDA margin (excluding share-based payment charge) of at least 25% (FY19 EBITDA margin was 27%)

Targets to be updated February 2024



Dividend

- Change of policy progressive year-on-year dividend increase by a minimum of 5%
- Full year dividend 2023 10.5p.
- Final dividend 2023 7.88p payable 22 December 2023







- ESG strategy published
- Carbon Zero target of 2030 and route to success defined
- Carbon profiling of key products underway with packaging adjustments and reductions planned
- Partnership with ESG consultants to ensure best practice adhered to
- Recruitment into specialist sustainability officer role underway
- Board evaluation completed, assisted by external advisors. Resulting actions undertaken
- Numerous staff wellbeing and support initiatives in place, alongside local community connections

Doing the right thing, in the right way



Summary & Outlook

- Strong set of results on all levels
- Global expansion to accelerate with North America launch
- Significant growth opportunity in both portfolios
- Profitable, cash generative, debt free, progressive dividend
- Exciting future ahead

Simple, focussed, global opportunity





Any questions?



APPENDIX – INCOME STATEMENT	Year ended	Year ended
	30.06.23	30.06.22
	£'000	£'000
Turnover	36,009	31,123
Cost of sales	(6,834)	(6,182)
Gross profit	29,175	24,941
Gross margin %	81%	80%
Administrative and distribution expenses less other operating income	(20,215)	(17,385)
Net interest	(169)	(194)
Operating profit before amortisation & shared based payments	8,791	7,362
Amortisation & Depreciation	(2,618)	(2,772)
Impairment of intangibles / Movement in fair value of investment	-	(2,439)
Share based payments	(1,061)	(596)
Pre-tax profit	5,112	1,555
Tax charge /(credit)	(651)	(568)
Profit after tax	4,461	987
Basic EPS – pence	9.44	2.09
Diluted EPS – pence	9.34	2.07



APPENDIX – BALANCE SHEET		
	30.06.23	30.06.22
Non-current assets	£'000	£'000
Goodwill	5,156	5,242
Intangible assets	4,757	4,138
Property, plant and equipment	7,827	8,359
Deferred tax	1,286	1,826
	18,693	19,565
Current assets		
Inventories	4,569	4,420
Trade and other receivables	7,081	5,851
Income tax receivable	1,146	962
Cash and short term investments	9,545	8,883
	22,341	20,116
Total assets	41,367	39,361

Continued...

APPENDIX – BALANCE SHEET ...Continued

	30.06.23	30.06.22
Capital and reserves	£'000	£'000
Share capital	474	473
Share premium account	14,188	13,996
Merger reserve	2,205	2,205
Foreign exchange reserve	(279)	(65)
Retained earnings	14,089	13,078
Non-controlling interests	7	7
Total equity	30,684	29,694
Current liabilities		
Trade and other payables	4,904	3,471
Other current liabilities	859	942
Total current liabilities	5,763	4,413
Deferred tax	599	720
Other non-current liabilities	4,321	4,854
Total liabilities	10,683	9,987
Total equity and liabilities	41,367	39,681

20 06 22



20 06 22

APPENDIX – CASH FLOW STATEMENT

Year ended	Year ended
30.06.23	30.06.22
£'000	£'000
5,112	1,555
3,917	6,021
(49)	(636)
(167)	(192)
(853)	(305)
(1,570)	(898)
(1,126)	(1,103)
(4,511)	(3,091)
193	398
(313)	(1,021)
29	61
662	789
	30.06.23 £'000 5,112 3,917 (49) (167) (853) (1,570) (1,126) (4,511) 193 (313) 29